Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARE1: ICI-ICI vs ICI-VEGFR TKI in Metastatic RCC
NCT06364631Phase 3Recruiting
- Sponsor
- Gustave Roussy
- Start
- Apr 2024
- Primary completion
- May 2032
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of nivolumab, ipilimumab, pembrolizumab, axitinib, cabozantinib and 1 more in metastatic renal cell carcinoma (mRCC), sponsored by Gustave Roussy. Primary endpoint: Overall Survival at 97 months. Started Apr 2024; status: recruiting.
02
Drugs
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT06364631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06364631.